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Abstract
Background: Pre-exposure prophylaxis (PrEP) is a promising new HIV prevention method, especially for women. An urgent
demand for implementation of PrEP is expected at the moment efficacy has been demonstrated in clinical trials. We
explored the long-term impact of PrEP on HIV transmission in different HIV epidemics.
Methodology/Principal Findings: We used a mathematical model that distinguishes the general population, sex workers
and their clients. PrEP scenarios varying in effectiveness, coverage and target group were modeled in the epidemiological
settings of Botswana, Nyanza Province in Kenya, and Southern India. We also studied the effect of condom addition or
condom substitution during PrEP use. Main outcome was number of HIV infections averted over ten years of PrEP use. PrEP
strategies with high effectiveness and high coverage can have a substantial impact in African settings. In Southern India, by
contrast, the number of averted HIV infections in different PrEP scenarios would be much lower. The impact of PrEP may be
strongly diminished or even reversed by behavioral disinhibition, especially in scenarios with low coverage and low
effectiveness. However, additional condom use during low coverage and low effective PrEP doubled the amount of averted
HIV infections.
Conclusions/Significance: The public health impact of PrEP can be substantial. However, this impact may be diminished, or
even reversed, by changes in risk behavior. Implementation of PrEP strategies should therefore come on top of current
condom campaigns, not as a substitution.
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Introduction
Behavioral changes, such as reduction in the number of sex
partners and the use of barrier methods in high-risk contacts, have
slowed down the HIV epidemic in many places in the world [1,2]
and will be of importance as long as no vaccine is available.
Condom use, the main barrier method, is mainly male-controlled.
Although condoms could, potentially, stop sexual HIV transmission
almost completely, new intervention strategies are still urgently
needed, especially those that can help women protect themselves. A
recent microbicides trial testing cellulose sulphate was stopped
prematurely because the gel was not only ineffective, but actually
increased HIV risk [3,4]. Furthermore, recent trials with a
diaphragm intervention method or with an HIV vaccine did not
show any benefit [5,6]. Pre-exposure prophylaxis (PrEP) seems a
promising new intervention [7–9] to fill the gap in female-controlled
prevention, but the method may be equally effective for males.
PrEP means that HIV-negative people regularly take antiretro-
viral (ARV) drugs to prevent infection [8,10,11]. The concept of
using ARV as a preventive method has been tested and proven
successful in prevention of mother-to-child transmission of HIV
[12]. Perhaps more significantly, post-exposure prophylaxis (PEP)
in health care workers immediately after accidental exposure to
HIV is common practice and may prevent 80% of the HIV
infections due to needle accidents [13].
Animal HIV challenge studies provided preliminary evidence
that PrEP might be partially effective in preventing HIV infection
[14–16]. The ARV drug tenofovir prevented simian immunode-
ficiency virus (SIV) infection in macaques, when given 48 hours
before an intravenous exposure to SIV [14]. Yet, while delaying
SIV infection, tenofovir could not fully prevent infection after
repeated viral challenges [15]. A combination of tenofovir and
emtricitabine (FTC) however provided a high level of protection in
humanized BLT mice [16].
To determine safety and efficacy of tenofovir and tenofovir/
FTC in humans, clinical trials are currently ongoing in young
adults (Botswana), injection drug users (Thailand), and men who
have sex with men (United States, Peru/Ecuador) [17]. Prelim-
inary results of a phase II safety trial among female sex workers in
Ghana, Nigeria and Cameroon showed that the use of tenofovir
was not associated with adverse events [18]. However, efficacy
could not be determined due to the low number of HIV infections.
Other trial results are expected at the earliest in 2008–2009
[17,19].
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Some fear that the use of PrEP may lead to more risky sexual
behavior because people may feel protected against HIV infection
[20,21]. This increase, which is called behavioral disinhibition or
risk compensation [22], would to some extent reduce the effect of
PrEP. Persons taking PrEP may feel protected against HIV
infection and consequently use fewer condoms. On the other
hand, PrEP users may be extensively counselled, be more aware of
their risk behaviour and the risks of unprotected sex, and may
therefore be more likely to use condoms. Nevertheless, whether or
not PrEP will lead to changes in risk behavior remains uncertain
especially if upscaling of services would lead to less effective
counselling.
PrEP will directly protect individuals taking it, but may also
have an indirect effect on non-PrEP users since reduced numbers
of HIV infections will lead to decreased transmission. Mathemat-
ical models can be used to estimate these indirect effects. Accurate
projections of the effect of PrEP on populations may help policy
makers in their decision process and planning of PrEP services in
AIDS control programmes. A demand for implementation of such
programmes is expected at the moment efficacy of tenofovir or
tenofovir/FTC against HIV transmission is proven in the different
clinical trials [19]. We used a mathematical model that has
previously been used to study the effect of HIV vaccines and male
circumcision [23,24]. In this study, we examined the long-term
effect of different levels of PrEP effectiveness on HIV transmission
in populations differing in HIV epidemiology.
Methods
HIV model
We adapted an existing compartmental HIV transmission
model to study the impact of PrEP on HIV epidemics in three
different regions, namely Botswana, Nyanza Province in Kenya
and Southern India [23,24]. This model divides the population in
groups of low-risk persons (not involved in sex work) and high-risk
persons (male clients and female sex workers), further subdivided
into compartments by HIV infection status, stage of infection, and
PrEP use. HIV infection was defined as early in the first four years
of infection and as late in the last four years. Per gender and risk
group, five compartments are distinguished in our model: HIV-
negative not using PrEP; HIV-negative using PrEP; HIV-early not
using PrEP; HIV-early using PrEP; and HIV-late not using PrEP.
AIDS and death are endpoints of the model.
Low-risk persons can become high-risk persons, and vice versa.
We only modeled heterosexual transmission. HIV can spread from
infected to uninfected persons by three relationship types. First,
HIV transmission can occur in sexual contacts between female sex
workers and their clients. Second, transmission can occur through
marriage-like relationships. Third, ‘‘leakage’’ from infected
individuals can occur reflecting all non-paid casual sex. HIV
transmission through marriage and ‘‘leakage’’ only occurs in low-
risk groups. Condom use is assumed in client-sex worker contacts,
but not in other types of sexual relationships.
All other assumptions underlying the original model can be
found elsewhere [23,24]. A technical description of the model
including compartments, flows, variables and parameters can be
found in the Appendix S1 and Figure S1. ModelMakerH (version
3.0.3) was used to implement and run the model.
Parameter values to model HIV epidemics in Botswana and
Nyanza were based on recent modeling work of Nagelkerke et al.
[24], who explored the effect of male circumcision. In our model,
circumcision was not taken into account. We slightly lowered the
former female-to-male transmission risk to adjust for the protective
effect of male circumcision. In earlier modeling work, condom use
in commercial sex was set at 20%. Data of Nyanza province from
1999 showed that 34–56% of clients and 75% of sex workers
reported that they always or usually used condoms during
commercial sex [25]. Therefore, we assumed that condom use in
commercial sex increased to 50% from 2000 onwards. All other
parameter values were kept identical to earlier values [24]. The
main difference between Botswana and Nyanza was the higher
‘‘leakage’’ in Botswana, reflecting an assumed higher number of
casual contacts in this country (see Appendix).
These parameter choices yielded approximate equilibrium HIV
prevalence levels of 33% in Botswana and 16% in Nyanza. In
Botswana, as the actual reported national HIV prevalence was
24% in 2005 [26], our model therefore probably only reflects the
worst affected parts of the country. In Nyanza, HIV prevalence
was estimated at 15% in 2003 [27], similar to the model’s
prediction.
In India, the southern states are the most affected area [28].
Condom use during commercial sex is more than 85% since 2000
[29]. We assumed that condom use in commercial sex was 60% in
1994 and increased to 90% from 1998 onwards. Besides the level
of condom use, the main difference between Botswana/Nyanza
and Southern India was a lower ‘‘leakage’’, reflecting an assumed
lower frequency of casual contacts in India (see Appendix).
Our modeled HIV prevalence in India was based on two data
sources. First, we used antenatal clinic (ANC) sentinel surveillance
data from Southern India, which showed a decline in HIV
prevalence from 1.8% in 1998 to 1.3% in 2004 [30,31]. Second,
we used a large, representative population based prevalence survey
in a rural area in South India which found an overall prevalence of
2.9% in 2003 [32]. Because the latter study had a larger sample
size and included the whole population instead of only pregnant
women, it might be more representative for Southern India than
the ANC data. Therefore, we simulated the decreasing trend of
ANC data, but ended slightly higher at a 1.3% prevalence in 2007.
Modeling PrEP
Only uninfected persons start taking PrEP. HIV-negatives can
be identified by either Client-Initiated Testing and Counselling
(CITC, formerly known as Voluntary Counselling and Testing) or
Provider-Initiated Testing and Counselling (PITC) [33]. The
coverage of PrEP is based on HIV-negative persons taking PrEP.
Some will stop taking pills (non-adherence). Since PrEP will most
likely not fully protect against HIV infection, persons may still get
infected, but at a lower rate than those not on PrEP. We assumed
that persons taking PrEP pills who get HIV infected, continue to
use PrEP on average for one year.
The use of a single drug, such as tenofovir, could promote HIV
resistance. However, a modeling study of the Botswana trial
estimated that of 600 participants receiving tenofovir, 45 persons
would seroconvert and less than one participant was expected to
acquire or develop a resistant HIV strain (Smith et al., 2006,
THAX0105–Antiretroviral resistance is not an important risk of
the oral tenofovir prophylaxis trial in Botswana: a simple
mathematical modelling approach, XVI International AIDS
Conference, Toronto, Canada). Therefore, we assumed that
taking PrEP pills will not lead to any resistance.
We assumed that PrEP would become available in 2012. We
predicted the effect of two strategies: targeting only sex workers or
targeting both sex workers and clients. This latter strategy
resembles a general population intervention with high-risk
individuals coming to clinics for PrEP. The efficacy of PrEP is
not known yet. We thus, somewhat arbitrarily, assumed a 50% or
90% effectiveness (i.e. reduced HIV susceptibility of those taking
PrEP). Coverages of persons taking PrEP varied per targeting
PrEP in Africa and India
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strategy. For Botswana/Nyanza, we explored a low (25%) or high
(75%) coverage. For Southern India, we assumed that targeting
with PrEP would result in higher coverage rates, since condom use
is also very high in commercial sex [29]. As taking one pill per day
might be as easy, or easier, than using a condom in each sex act,
we assumed that PrEP coverage rates in Southern India were 50%
and 95%, respectively.
We supposed that when sex workers and clients who use PrEP
pills stop their high-risk behaviour and become low-risk individ-
uals, they will also stop taking PrEP pills (i.e. they are no longer
part of the target group). Main outcomes were HIV prevalence,
number of HIV infections averted over ten years of PrEP use (i.e.
in 2022), and amount of PrEP needed in ten years. Both averted
infections and amount of PrEP were calculated per 100,000 HIV-
negative adult person years.
To explore alternatives to PrEP, we also modelled an
intervention resulting in increased condom use in client-sex
worker contacts. In this intervention, condom use was assumed
to increase in 2007 (and not in 2012 like the PrEP strategies, since
it is already available) from 50% to 75% in Botswana/Nyanza,
and from 90% to 95% in Southern India. Thus, in both situations
we assumed that the number of non-users was halved. Further-
more, we explored the effect of less (i.e. condom substitution) or
more (i.e. condom addition) condom use during PrEP interven-
tions. In substitution scenarios, the level of condom use was
assumed to be 15% lower, 35% in Botswana/Nyanza and 75% in
India (i.e. halfway the levels in 2007 and 2000 or 1998,
respectively). In addition scenarios, condom use was assumed to
be halfway that of the condom intervention level, 62.5% in
Botswana/Nyanza and 92.5% in India.
Results
The impact of different PrEP strategies and the condom
intervention on HIV prevalence in Botswana and Nyanza over the
period 2006–2022 is shown in Figure 1. PrEP strategies with high
coverage and high effectiveness targeting only sex workers or both
sex workers and clients have a substantial impact on HIV
prevalence. In both settings, the condom intervention and the high
PrEP scenario targeting both sex workers and clients resulted in
comparable HIV prevalences in 2022.
Figure 2 shows the baseline fit in Southern India. A PrEP
scenario with 50% coverage and 50% effectiveness targeting only
sex workers with three different condom options is also depicted.
Condom substitution (i.e. 15% less use) during the PrEP scenario,
resulted in a higher HIV prevalence, however, the prevalence was
still decreasing. HIV prevalence no longer decreased if condom
use during PrEP was reduced to 60% (i.e. 30% less use).
Results of different PrEP strategies and condom substitution or
condom addition during PrEP are given in Table 1. The number
of infections averted varied from 26 to 785 per 100,000 uninfected
adult person years in Botswana, and from 44 to 733 per 100,000
person years in Nyanza. The number of averted infections was,
even with higher coverages, considerably lower in Southern India:
only 0.9 to 6.0 averted infections per 100,000 person years. The
amount of PrEP pills needed in a 10-year period varied from
around 50,000 to around 2 million pills per 100,000 person years
in the African settings. Slightly more PrEP pills were needed in
Southern India (Table 1).
Condom substitution (i.e. 15% less condom use during PrEP
scenarios) reduced the number of infections averted in all three
settings in all four PrEP scenarios (Table 1). In PrEP scenarios with
both low coverage and low effectiveness, condom substitution even
led to an increase in the number of HIV infections in all three
settings. In Botswana and in Southern India, the impact of the
high PrEP scenario targeting only sex workers was also nullified by
condom substitution. The effect of the high PrEP scenario
targeting both sex workers and clients was substantially reduced,
but not nullified, by condom substitution.
In African settings, the effect of condom addition (i.e. 15% more
condom use during PrEP scenarios) was highest in low PrEP
scenarios targeting sex workers only (Table 1). Additional condom
use during the low PrEP scenarios targeting both sex workers and
clients more than doubled the number of averted HIV infections.
Condom addition in the high PrEP scenarios resulted in 10 to
100% more averted infections.
The impact of condom addition in Southern India (i.e. 2.5%
more condom use during PrEP scenarios) was high in low PrEP
scenarios (80 to 300% more averted infections). In high PrEP
scenarios, condom addition resulted in 3 to 20% more averted
HIV infections.
Discussion
PrEP strategies with high efficacy and high coverage can have a
substantial impact in African settings. In Southern India, by
contrast, the number of averted HIV infections in different PrEP
scenarios would be much lower. The impact of PrEP may be
strongly diminished or even reversed by behavioral disinhibition,
especially in scenarios with low coverage and low effectiveness.
However, additional condom use during low coverage and low
effective PrEP doubled the amount of averted HIV infections.
We did not model ART treatment in the different epidemics.
Since ART and PrEP could be the same drugs and ART is being
scaled-up in many resource-poor countries, it is very unlikely that
in reality PrEP would be introduced in an area without ART.
ART coverage among HIV-infected adults in need of ART
according to WHO criteria was estimated to be 79% in Botswana,
33% in Kenya and 4–9% in India by the end of 2006 (www.who.
int/globalatlas/default.asp). Furthermore, we ignored the effect of
PrEP on onward transmission, although an approximate 80%
reduction in HIV transmission was shown in discordant couples
where HIV-positive partners were taking ART [34]. PrEP users
who become infected may also have reduced infectivity. Arguably,
we may thus have underestimated the overall effect of PrEP use on
HIV spread.
In our model, PrEP users who got HIV infected remained on
PrEP on average for one year. This was done to reflect the reality
that persons taking PrEP who get infected will be unaware of their
changed HIV status until being tested again. Thus, in our model,
condom substitution also affects such HIV-positive individuals
making the effect of such substitution worse. Frequent HIV testing
would moderate this adverse effect, but also put a heavy additional
burden on health care resources.
We found that PrEP strategies could have a substantial impact
in African settings. Another recent modeling study estimated a
comparable impact of PrEP in sub-Saharan Africa [35]. In
Botswana, we found 29,399 averted infections and 3,745,054
HIV-negative adult person years resulting in 785 averted
infections per 100,000 person years (Table 1). The number of
person years on PrEP was 216,541. Converting our result in
averted infections per person year on PrEP, like Abbas et al. did,
we found 0.14 averted infections per person year. They found 0.33
averted HIV infections in a similar PrEP scenario (i.e. 90%
effectiveness, 75% coverage, targeting high-risk individuals) [35].
The difference might be explained by the different model
assumptions. We modeled high-risk behavior explicitly by
including sex workers and clients, who were in these compart-
PrEP in Africa and India
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ments for a certain period (on average four years for sex workers
and ten years for clients) and afterwards changed to low-risk
individuals. Abbas et al. used four different sexual activity levels,
that lasted lifelong. Moreover, they also included reduced
infectivity when a PrEP user got infected with HIV, which was
not in our model.
We performed sensitivity analyses of PrEP coverage in all three
settings. We changed PrEP coverage in steps of 5% with both
PrEP efficacy levels (50% and 90%) and both target groups (CSW
only and CSWs & clients), ranging from 15–35% and 65–85% in
African settings and from 40–60% and 80–99% fro Southern
India. In Southern India, we also looked at low coverage varying
from 15% to 35%, which is comparable to the African settings. We
found that the number of averted HIV infections in the period
2012–2022 was almost proportional to the coverage of PrEP. For
the interventions directed at CSW only, there was a modest
additional effect with higher PrEP coverage due to a slightly
reduced level of transmission within the population (results not
shown).
One of the added values of our study is that we also modeled the
impact of PrEP in Southern India. The number of HIV infections
averted was much lower than in the African settings. This is
Figure 1. Effect of different PrEP scenarios and condom use on HIV prevalence. A: Botswana, B: Nyanza province, Kenya. ‘PrEP low’ means
25% coverage and 50% effectiveness; ‘PrEP high’ means 75% coverage and 90% effectiveness; ‘Only CSW’ means target group is sex workers;
‘CSW&client’ means target group is sex workers and clients.
doi:10.1371/journal.pone.0002077.g001
PrEP in Africa and India
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Figure 2. HIV prevalence in women in Southern India. Depicted are the baseline fit and the effect of different PrEP scenarios and condom use.
*NACO, 2005 [30]; **Kumar et al., 2006 [31]; ***Becker et al., 2007 [32]. ‘PrEP low’ means 50% coverage and 50% effectiveness; ‘Only CSW’ means
target group is sex workers; ‘Same’ means unchanged condom use during PrEP (90%); ‘Less’ means condom substitution during PrEP (condom use is
75% or 60%).
doi:10.1371/journal.pone.0002077.g002
Table 1. Impact of different PrEP scenarios in Botswana, Nyanza and Southern India.
Setting–PrEP scenariosa
PrEP
efficacy
(%)
PrEP
coverage
(%)
PrEP
pillsc
(6106) Averted HIV cases
d in case condom use was:
Same 50/90%e Less 35/75%e More 62.5/92.5%e
Botswana (N = 516,000b)
Low–sex workers 50 25 0.04 26 2221 288
High–sex workers 90 75 0.18 251 214 503
Low–sex workers/clients 50 25 0.83 159 280 403
High–sex workers/clients 90 75 2.11 785 640 909
Nyanza (N = 837,000b)
Low–sex workers 50 25 0.06 44 2236 325
High–sex workers 90 75 0.23 342 75 564
Low–sex workers/clients 50 25 0.77 166 2100 419
High–sex workers/clients 90 75 1.92 733 610 831
Southern India (N = 235,000,000b)
Low–sex workers 50 50 0.25 0.9 216.5 2.7
High–sex workers 90 95 0.51 3.8 22.2 4.6
Low–sex workers/clients 50 50 1.50 1.8 211.4 3.3
High–sex workers/clients 90 95 2.66 6.0 4.4 6.2
aAll PrEP scenarios started in 2012. ‘Low’ and ‘high’ refer to PrEP effectiveness and PrEP coverage; ‘sex workers’ and ‘sex workers/clients’ refer to the different target
groups.
bAdult population size in 2012.
cNumber of PrEP pills per 100,000 uninfected adult person years needed in the period 2013–2022 in scenarios in which condom use was unchanged.
dNumber of averted HIV infections per 100,000 uninfected adult person years in the period 2013–2022.
e‘Same’ means unchanged condom use during PrEP: 50% in Botswana/Nyanza and 90% in Southern India; ‘Less’ means condom substitution during PrEP (i.e. less
condom use): 35% in Botswana/Nyanza and 75% in Southern India; ‘More’ means condom addition during PrEP (i.e. more condom use): 62.5% in Botswana/Nyanza and
92.5% in Southern India.
doi:10.1371/journal.pone.0002077.t001
PrEP in Africa and India
PLoS ONE | www.plosone.org 5 May 2008 | Volume 3 | Issue 5 | e2077
primarily due to the high levels of condom use during commercial
sex in Southern India that have resulted in a steeply decreasing
HIV trend since 2000 [29–31]. If PrEP would even slightly
decrease current condom use levels in India, its impact would be
negative. Furthermore, India is a densely populated country where
about 300 million people live in the Southern states at this moment
(www.censusindia.gov.in). The population grows with 1.4% per
year, resulting in about 370 million people in 2022. On a
population level, around 2,700 HIV infections can be averted in
Southern India in a 10-year PrEP scenario targeting 50% of the
sex workers and with 50% effectiveness. However, if during this
PrEP scenario 15% less condoms are used, this leads to an
additional 51,000 HIV infections, and even 180,000 more
infections if condom use goes down to 60%. Thus, in India
introduction of new prevention methods such as PrEP must be
done very carefully in order not to compromise the benefits gained
through condom use.
Prophylaxis can be a useful method to prevent HIV infection,
especially for women. However, large-scale PrEP use might
encounter problems such as poor adherence and resistance. In a
study in Zambia, 30% of tuberculosis patients in a Directly
Observed Therapy programme stopped medication prematurely,
before the completion of the scheduled 8-month treatment course
[36], and adhering to pills for disease prevention might even be
more difficult than for treatment. Clearly, assuring long-time
adherence might be one of the tremendous difficulties facing PrEP
services.
One of the problems of intermittent use, besides reduced
effectivity, is possible emergence of resistant viruses. We assumed
that PrEP use would not lead to resistance to ART drugs, based on
the modeling work of Smith et al for a clinical trial situation in
Botswana (2006, THAX0105–Antiretroviral resistance is not an
important risk of the oral tenofovir prophylaxis trial in Botswana: a
simple mathematical modelling approach, XVI International
AIDS Conference, Toronto, Canada). PrEP use on a wider scale
outside trial settings with more people taking PrEP, a higher risk of
non-adherence, and possible changes in risk behavior due to less
extensive counseling may well lead to the emergence of resistant
strains. Although usage of PrEP pills that contain two or more
different ARV drugs may decrease the risk of development of
resistance, it may not ultimately prevent it.
We have demonstrated that disinhibition during PrEP services is
important and may have a considerable effect on HIV epidemics.
To what extent disinhibition will actually occur is still uncertain.
Earlier studies of the effect of PEP or ART on disinhibition
reported conflicting results. Studies of PEP in homosexual men in
the US did not demonstrate an increase in risky sexual behavior
[37,38]. Similarly, a meta-analysis on sexual behavior and ART in
industrialized countries did not reveal an increase in risky behavior
of persons receiving ART compared to those who did not, except
in those who believed that therapy prevented transmission [39].
Providing ART and counseling was even associated with reduced
sexual risk behavior in Uganda [40]. In South Africa, by contrast,
high levels of unprotected sex were reported both by persons on
ART and by those not yet eligible for ART [41].
Condom addition had a substantial impact on the number of
averted HIV infections in the different PrEP scenarios. People
coming for HIV-testing and PrEP should be extensively counseled
about the necessity to continue or enhance habits of safe sex, such
as use of condoms. Furthermore, PrEP pills could be distributed in
combination with condoms. Changes in risk behavior can be
assessed by repeated sexual behavior surveys or by STD screening
when people visit clinics for scheduled PrEP pills collections.
We conclude that PrEP can have a substantial impact in the
reduction of HIV. Targeting high-risk groups is relatively easy and
inexpensive and would result in comparable HIV prevalences as
successful condom interventions. However, policy makers should
be aware of changes in risk behavior. Especially in Southern India,
where condom use is already very high during commercial sex,
small changes could have strong negative effects. Implementation
of PrEP strategies should come on top of current condom
campaigns, not as a substitution.
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